Development of Antiretroviral Drug Resistance, New England Journal of Medicine, vol.365, issue.7, pp.637-646, 2011. ,
DOI : 10.1056/NEJMra1004180
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48, AIDS, vol.22, issue.12, pp.1389-1397, 2008. ,
DOI : 10.1097/QAD.0b013e32830285fb
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study, The Lancet, vol.372, issue.9639, pp.646-655, 2008. ,
DOI : 10.1016/S0140-6736(08)61081-8
Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy, Antimicrobial Agents and Chemotherapy, vol.53, issue.7, pp.2934-2939, 2009. ,
DOI : 10.1128/AAC.01643-08
Failure of Treatment with First???Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V, The Journal of Infectious Diseases, vol.200, issue.5, pp.698-709, 2009. ,
DOI : 10.1086/605329
Prevalence of Darunavir Resistance???Associated Mutations: Patterns of Occurrence and Association with Past Treatment, The Journal of Infectious Diseases, vol.196, issue.8, pp.1177-1179, 2007. ,
DOI : 10.1086/521624
Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance, AIDS, vol.22, issue.2, pp.311-313, 2008. ,
DOI : 10.1097/QAD.0b013e3282f4244f
Virological Failure and HIV Type 1 Drug Resistance Profiles Among Patients Followed-up in Private Sector, Douala, Cameroon, AIDS Research and Human Retroviruses, vol.27, issue.2, pp.221-230, 2011. ,
DOI : 10.1089/aid.2010.0103
Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir, Antimicrobial Agents and Chemotherapy, vol.52, issue.2, pp.491-496, 2008. ,
DOI : 10.1128/AAC.00909-07
Prevalence, Mutation Patterns, and Effects on Protease Inhibitor Susceptibility of the L76V Mutation in HIV-1 Protease, Antimicrobial Agents and Chemotherapy, vol.54, issue.11, pp.4903-4906, 2010. ,
DOI : 10.1128/AAC.00906-10
The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?, AIDS Research and Therapy, vol.8, issue.1, p.7, 2011. ,
DOI : 10.1001/jama.2010.1004
Both a Protective and a Deleterious Role for the L76V Mutation, Antimicrobial Agents and Chemotherapy, vol.53, issue.4, pp.1724-1725, 2009. ,
DOI : 10.1128/AAC.01693-08
2011 update of the drug resistance mutations in HIV-1, Top Antivir Med, vol.19, pp.156-164, 2011. ,
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure, AIDS, vol.18, issue.12, pp.11-19, 2004. ,
DOI : 10.1097/01.aids.0000131394.76221.02
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients na??ve to the antiretroviral drugs, BMC Infectious Diseases, vol.18, issue.suppl, p.111, 2009. ,
DOI : 10.1097/00002030-200401230-00012
Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations prevalence in HIV-1-infected patients experiencing virological failure between, Abstract of the 19 th Conference on Retroviruses and Opportunistic Infections, 2005. ,
Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?, Journal of Medical Virology, vol.30, issue.10, pp.1677-1681, 2011. ,
DOI : 10.1093/ije/30.4.864
Resistance Mutations in Subtype C HIV Type 1 Isolates from Indian Patients of Mumbai Receiving NRTIs Plus NNRTIs and Experiencing a Treatment Failure: Resistance to AR, AIDS Research and Human Retroviruses, vol.23, issue.2, pp.335-340, 2007. ,
DOI : 10.1089/aid.2006.0183
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors, AIDS, vol.17, issue.1, pp.1-5, 2003. ,
DOI : 10.1097/00002030-200301030-00001
Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes, Antivir Ther, vol.14, pp.123-129, 2009. ,
Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients, J Virol, vol.72, pp.7632-7637, 1998. ,
Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss, PLoS Pathogens, vol.166, issue.3, p.1000345, 2009. ,
DOI : 10.1371/journal.ppat.1000345.s001
A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism, PLoS Medicine, vol.30, issue.1, p.36, 2007. ,
DOI : 10.1371/journal.pmed.0040036.st001
Polymorphism in Gag Gene Cleavage Sites of HIV-1 Non-B Subtype and Virological Outcome of a First-Line Lopinavir/Ritonavir Single Drug Regimen, PLoS ONE, vol.10, issue.7, p.24798, 2011. ,
DOI : 10.1371/journal.pone.0024798.s001